Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Circulating insulin: the proinsulin-like properties of “big” insulin in patients without islet cell tumors
Barry M. Sherman, Phillip Gorden, Jesse Roth, Pierre Freychet
Barry M. Sherman, Phillip Gorden, Jesse Roth, Pierre Freychet
View: Text | PDF
Research Article

Circulating insulin: the proinsulin-like properties of “big” insulin in patients without islet cell tumors

  • Text
  • PDF
Abstract

When plasma is filtered on Sephadex G-50, insulin immunoreactivity is recovered in two peaks. “Big” insulin, the higher molecular weight component, and “little” insulin, the lower molecular weight component, have elution volumes that correspond to those of proinsulin-125I and insulin-125I respectively. When plasma was extracted with acid ethanol and filtered in 1.0 M acetic acid, the patterns and proportions of “big” and “little” insulin were indistinguishable from those obtained by filtration of whole plasma in neutral buffer. When “big” insulin was isolated from plasma and mixed with a tracer of porcine proinsulin-125I, trypsin converted the “big” insulin immunoreactivity to the gel filtration pattern of “little” insulin in the same way that it converted the proinsulin radioactivity. More than 90% of both “big” insulin and proinsulin were converted at optimal trypsin concentrations. Our present guinea pig anti-insulin serum failed to distinguish “big” from “little” but a porcine proinsulin anti-serum, under appropriate conditions of assay, reacted strongly with “big” insulin but not at all with “little.” When tested on isolated fat cells, “little” insulin had the same bioactivity as porcine insulin, whereas “big” insulin had the same low activity as porcine proinsulin. These studies suggest that “big” insulin represents either single-chain proinsulin and/or a proinsulin intermediate that has similar low bioactivity.

Authors

Barry M. Sherman, Phillip Gorden, Jesse Roth, Pierre Freychet

×

Full Text PDF


Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts